Sienna Cancer Diagnostics

Follow
Get notifications in MyBN when activity occurs.

Melbourne-based Sienna Cancer Diagnostics is a public listed company with global operations. Head office and laboratories are located within the Small Technologies Cluster, a successful and thriving environment where a number of biotechnology and other high technology businesses have their research and development, commercialisation and manufacturing operations.

Sienna's focus is in creating a portfolio of unique and clinically useful tests for the pathology diagnostics market and clinical diagnostic laboratories worldwide.

In July 2020, the company was acquired by BARD1 Life Sciences.

Article Timeline

Company Activity

BARD1 raises $15m for cancer detection tests
NEWS: Tagged in BARD1 raises $15m for cancer detection tests23 Jul 2021
BARD1 soars on cancer tech update
NEWS: Tagged in BARD1 soars on cancer tech update15 Feb 2021
Tony Di Pietro
NEW ROLE: Tony Di Pietro, Chief Financial Officer, Company Secretary03 Aug 2020
Tony Di Pietro
NEW ROLE: Tony Di Pietro, Executive Director03 Aug 2020
Carl Stubbings
NEW ROLE: Carl Stubbings, Managing Director, Chief Executive03 Aug 2020
Carl Stubbings
NEW ROLE: Carl Stubbings, Non-Executive Director03 Aug 2020
Helen Fisher
NEW ROLE: Helen Fisher, Non-Executive Director03 Aug 2020
Geoffrey Cumming
NEW ROLE: Geoffrey Cumming, Non-Executive Chair03 Aug 2020
Peter French
NEW ROLE: Peter French, Strategic Technology Advisor24 Jul 2020

STANDING BY BUSINESS. TRUSTED BY BUSINESS.

Subscription Options